CMS has set a device intensive status for the procedure, meaning the total cost of the device is included in the reimbursement rate for ASCs, according to a March 9 press release by Gynesonics.
The reimbursement for ASCs will be $3,632.42 for the transcervical uterine fibroid ablation. For Sonata procedures performed in a hospital outpatient setting, ambulatory payment classification has increased to $6,794.31.
More articles on physicians:
There were 226 ASCs opened in 2019 & 3 more MedPAC 2021 report highlights
Missouri medical group breaks ground on outpatient surgery center
Bundled payments in ASCs: Good business or a race to the bottom?
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.